The National Institutes of Health exists to fund scientific research into some of the most serious medical problems facing Americans — cancer, heart disease, Alzheimer's disease, infectious diseases and countless other conditions.
President Donald Trump now reportedly wants to put another layer of White House control between scientists and billions of dollars in federal research funding.
Trump has directed Office of Management and Budget Director Russ Vought to draft an executive order that would establish a new board overseeing which NIH grants receive funding.
The proposal could give one of Trump's most powerful political appointees direct influence over the distribution of roughly $48 billion appropriated by Congress for the NIH.
And it comes after Congress already moved to temporarily block an earlier White House effort to exert greater political control over federal research grants.
A New Board Between Scientists and Their Funding
Under the reported proposal, the new board would include Vought and NIH Director Jay Bhattacharya.
Grant decisions would require unanimous approval.
That detail is significant.
Giving Vought a required vote would effectively give the White House budget director the ability to prevent grants from moving forward even after they had traveled through the scientific grant-review process.
Traditionally, NIH research grants undergo extensive peer review involving scientists and subject-matter experts who evaluate proposals for factors such as scientific merit and potential impact.
The Trump administration has argued that changes are necessary to ensure taxpayer-supported research reflects administration priorities and that federal money isn't supporting research it considers wasteful or ideologically driven.
Critics see something very different: political officials gaining more power over decisions traditionally driven heavily by scientific review.
Congress Already Tried to Stop This
Perhaps the most remarkable part of the story is that Congress has already intervened.
Earlier this month, the House overwhelmingly approved a stopgap spending bill containing language temporarily blocking a White House proposal to give political appointees greater control over federal research grants.
The House vote was 370-48.
The Senate had already approved the same legislation.
That prohibition, however, is temporary.
It expires December 11.
Now Trump has reportedly instructed Vought to prepare an executive order establishing another mechanism for reviewing NIH grants.
The administration has not publicly detailed the final structure of the proposed order, and because it remains under development, precisely how broadly the board's authority would operate remains unclear.
But the direction is difficult to miss.
The White House wants more control.
Science Has Already Become a Political Battleground
The proposal doesn't arrive in isolation.
Since Trump returned to office, his administration has repeatedly challenged federal research grants it considers inconsistent with its priorities.
NIH grants have faced scrutiny involving subjects such as diversity, health disparities, climate change and gender identity.
Researchers filed a new lawsuit this month alleging that NIH has been screening grants using hundreds of keywords and suppressing research based on whether subjects conflict with administration priorities.
The government disputes accusations that its policies amount to unconstitutional viewpoint discrimination and has defended its efforts as legitimate decisions about what taxpayers should fund.
The courts are still sorting through those arguments.
But researchers have already reported changing the language in grant applications to avoid terms likely to attract additional scrutiny.
Now the administration reportedly wants to place another review body above the existing process.
Medical Research Should Not Become a Political Loyalty Test
Presidents have every right to establish policy priorities, propose budgets and argue that federal money should be spent differently.
Congress likewise has the constitutional authority to appropriate federal money.
But there is a fundamental difference between establishing broad national research priorities and allowing political appointees to effectively veto individual scientific grants.
Cancer does not care which party controls the White House.
Neither does Alzheimer's disease.
Neither do Parkinson's disease, diabetes, heart disease or thousands of rare diseases affecting American families.
The question surrounding a medical research proposal should be whether the science is sound, whether the research is worthwhile and whether it could advance human knowledge or improve health.
It should not be whether a proposal passes an ideological test inside the White House.
Another Attempt to Centralize Power
The administration's argument is that elected officials should have greater accountability over how taxpayer money is spent.
There is a legitimate debate to be had about federal research priorities and whether the NIH always spends its enormous budget wisely.
But Trump's reported proposal goes considerably further than simply demanding accountability.
It would insert senior political officials directly into the grant-approval process.
And Congress has already demonstrated substantial bipartisan concern about moving federal research funding in that direction.
That apparently hasn't ended the effort.
Instead, Trump is reportedly looking for another route.
America became a global leader in biomedical research because generations of scientists were allowed to investigate difficult questions, challenge assumptions and pursue discoveries whose importance was not always immediately obvious.
Political leaders come and go.
Scientific discoveries can change human life for generations.
The White House should be extremely careful before turning the distribution of medical research money into another arena for presidential political control.